Working For Both Opioid Maker And Fda Wasnt Battle, Mckinsey Tells Committee
Future vaccines with improved efficacy profiles might then complement vaccines that have been approved earlier. In our evaluation, we accounted for differences in development timelines and within the platform technologies getting used. If a vaccine candidate isn’t beginning a scientific trial until 2021, for instance, it may face funding or trial-recruitment challenges that would delay…